 clipped from bl101fd.blu101.hotmail.msn.comThere are also potential concerns over its #4-selling TriCor fat-reducing drug: A March study by Dr. Steven Nissen showed that 19 patients (38%) in a control group that took fenofibrate (its generic name) saw their creatinine levels rise above the upper limits of normal, which could reduce kidney function and increase cardiac events. Nissen, who previously raised concerns over Glaxo's (GSK) Avandia Merck's (MRK) painkiller Vioxx, says he will not prescribe the drug.
|
Monday, June 4, 2007
TriCor
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment